Industry Watch

2010 ◽  
Vol 14 (10) ◽  
pp. 35-52
Keyword(s):  
Cell Therapy ◽  
Progenitor Cell ◽  
Agricultural Sciences ◽  
Treatment Of Diabetes ◽  
Bt Gene ◽  
Hep B

MDI and Integrated Sciences Enter Exclusive Distribution Agreement in Australia. Agenix, IMB to Develop Hep B Drug in China. NeoStem to Acquire Progenitor Cell Therapy in $20m Deal. Origin Biotechnology Reaches Worldwide Agreement with Chinese Academy of Agricultural Sciences for Bt-gene. Transasia Bio-Medicals Acquires Pliva Lachema Diagnostika. Advinus Team Discovers Novel Molecule for Treatment of Diabetes. Biocon Partners with Teleradiology Solutions. Abbott, Reata Pharma Collaborate on Kidney Treatment.

Topical Lineage-Negative Progenitor-Cell Therapy for Diabetic Wounds

2008 ◽  
Vol 122 (5) ◽  
pp. 1341-1351 ◽  
Author(s):  
Clarence D. Lin ◽  
Alexander C. Allori ◽  
Jared E. Macklin ◽  
Alexander M. Sailon ◽  
Rica Tanaka ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Progenitor Cell ◽  
Diabetic Wounds

scholarly journals Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Peter A. Walker ◽  
Matthew T. Harting ◽  
Shinil K. Shah ◽  
Mary-Clare Day ◽  
Ramy El Khoury ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Cell Therapy ◽  
Progenitor Cell ◽  
Neurological Injury ◽  
Cell Therapies ◽  
Potential Efficacy ◽  
Cord Injury

Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials.

Progenitor Cell Therapy in Patients With Critical Limb Ischemia Without Surgical Options

2008 ◽  
Vol 247 (3) ◽  
pp. 411-420 ◽  
Author(s):  
Ralf W. Sprengers ◽  
Daniel J. Lips ◽  
Frans L. Moll ◽  
Marianne C. Verhaar
Keyword(s):  
Cell Therapy ◽  
Critical Limb Ischemia ◽  
Progenitor Cell ◽  
Limb Ischemia ◽  
Surgical Options

scholarly journals Tissue Engineering Approaches for Enamel, Dentin, and Pulp Regeneration: An Update

2020 ◽  
Vol 2020 ◽  
pp. 1-15 ◽  
Author(s):  
Geraldine M. Ahmed ◽  
Eman A. Abouauf ◽  
Nermeen AbuBakr ◽  
Christof E. Dörfer ◽  
Karim Fawzy El-Sayed
Keyword(s):  
Cell Therapy ◽  
Progenitor Cells ◽  
Progenitor Cell ◽  
Clinical Applications ◽  
Multilineage Differentiation ◽  
Differentiation Potential ◽  
Self Renewal ◽  
Dental Tissues ◽  
Undifferentiated Cells ◽  
Different Sources

Stem/progenitor cells are undifferentiated cells characterized by their exclusive ability for self-renewal and multilineage differentiation potential. In recent years, researchers and investigations explored the prospect of employing stem/progenitor cell therapy in regenerative medicine, especially stem/progenitor cells originating from the oral tissues. In this context, the regeneration of the lost dental tissues including enamel, dentin, and the dental pulp are pivotal targets for stem/progenitor cell therapy. The present review elaborates on the different sources of stem/progenitor cells and their potential clinical applications to regenerate enamel, dentin, and the dental pulpal tissues.

Sign in / Sign up

Export Citation Format

Share Document